First-line trastuzumab deruxtecan significantly improves progression-free survival in HER2-mutant lung cancer
First-line treatment with trastuzumab deruxtecan (T-DXd) significantly improved progression-free survival compared with pembrolizumab plus platinum-based chemotherapy in patients with advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC), according to primary results from the phase 3 DESTINY-Lung04 trial presented at the International Association for the Study of Lung Cancer…
In a groundbreaking phase 3 trial, trastuzumab deruxtecan (T-DXd) demonstrated superior results compared to the standard therapy of pembrolizumab plus platinum-based chemotherapy in patients with advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC). The DESTINY-Lung04 trial, a global study, showed that T-DXd led to a significant 6-month improvement in median progression-free survival, which increased from 8.3 months to 14.3 months.
Additionally, T-DXd produced a higher objective response rate of 70.0% compared to 44.5% with the standard treatment. Despite these improvements, overall survival was not significantly affected by T-DXd, and a notable side effect was interstitial lung disease/pneumonitis, which occurred in 20.8% of T-DXd patients compared to 2.3% in the standard treatment group.
These findings suggest that T-DXd could be a promising new option for first-line treatment of HER2-mutant NSCLC, addressing the need for more effective HER2-directed therapies.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
